Previous 10 | Next 10 |
Catalyst Biosciences press release ( NASDAQ: CBIO ): Q2 GAAP EPS of $1.64. At the end of the second quarter, the Board expected the total amount of cash to be distributed to stockholders to be up to $65.0 million in one or more distributions Cash and cash equivalents a...
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its operating and financial results for the second quarter ended June 30, 2022. “We were very pleased to ...
Catalyst Biosciences is highly committed to its cash distribution plan to shareholders of up to $65 million in the near future, with only a $58 million market capitalization. If the proxy contest is cleared up between Catalyst and JDS1 and goes in favor of the executives of Catalyst, ...
JDS1, LLC (“JDS1”), which collectively with the other reporting persons in its Section 13(d) group, beneficially owns approximately 8.4% of the outstanding common stock of Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst” or the “Company...
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company,” “Catalyst” or “we”) announced that it has received a notice from JDS1, LLC (“JDS1”) that JDS1 has withdrawn the no...
ISS and Glass Lewis Highlight That Stockholders Are Best Served by Allowing the Incumbent Board to Pursue Its Cash Distribution Plan Catalyst Urges Stockholders to VOTE “FOR” All of the Company’s Nominees SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEW...
Provides Details on Current Board’s Cash Distribution Plan and Efforts to Maximize the Amount of Cash Available for Distribution Company Commits to Distributing $45 Million to Stockholders in an Initial Distribution, if Proxy Contest and Litigation End Soon, and Without M...
JEC Capital Partners Agrees to Vote Its Shares in Favor of Catalyst’s Nominees at the Company’s 2022 Annual Meeting Michael Torok from JEC Appointed as an Observer to the Transaction Committee of the Board of Directors Company Has Committed to Announcing a ...
Reiterates the Board’s Commitment to Expeditiously Distributing All of the Company’s Available Cash to Stockholders, Net of Liabilities and Obligations Warns Stockholders that JDS1 May Have Ulterior Motives in Running a Proxy Contest: Gaining Control of the Company...
Court Denies JDS1’s Motion for Expedited Proceedings Board Reiterates Commitment to Distributing Cash to Stockholders Once Potential Liability and Expenses Associated with Stockholder Litigation and Proxy Contest Are Known SOUTH SAN FRANCISCO, Calif., July 06, 2022 ...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Biosciences Inc. Company Name:
CBIO Stock Symbol:
NASDAQ Market:
Catalyst Biosciences Inc. Website:
The combined company will operate as “Gyre Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “GYRE” effective Tuesday, October 31, 2023 SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq: CBIO) (“...
Catalyst Biosciences Inc. (CBIO) is expected to report $-0.05 for Q3 2023
NEW YORK, NY / ACCESSWIRE / March 1, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Broadmark Realty Capital Inc. (NYS...